Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

Gencor Releases Third Quarter Fiscal 2025 Results

ORLANDO, Fla., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Gencor Industries, Inc. (the “Company” or “Gencor”) (NYSE American: GENC) announced today net revenue increased 5.6% for the quarter ended June 30...

Could the revenue growth trigger any technical chart patterns or trigger stop‑loss orders for existing positions? What is the market's reaction to the earnings surprise, and does it indicate a shift in investor sentiment toward Gencor? How does the current valuation (e.g., P/E, EV/EBITDA) of Gencor compare to its historical averages and to competitors after this earnings release?
Symbol: GENC
Earnings
22 days ago
Read more globenewswire

TeraWulf Reports Second Quarter 2025 Results

On schedule and on budget to deliver 72.5 MW of gross HPC hosting infrastructure to Core42 in 2025.

What is the expected impact on the company's balance sheet, particularly cash flow and capital expenditures, after completing the Core42 deployment? How might the sentiment score of 60 translate into market perception and short‑term price momentum? What macro‑economic or regulatory factors could influence the valuation of WULF following this earnings release?
Symbol: WULF
Earnings
22 days ago
Read more globenewswire

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

NEWTOWN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies...

What is the outlook for the company's operating expenses and R&D spend in the upcoming quarters, and how might that influence profitability trends? Are there any upcoming catalysts (e.g., data readouts, FDA meetings) that could drive the stock price in the near term? What was the market reaction to the earnings release and conference call, and are there any immediate price implications for the stock?
Symbol: TRAW
Earnings
22 days ago
Read more globenewswire

American Lithium Announces Management Change

VANCOUVER, British Columbia, Aug. 08, 2025 (GLOBE NEWSWIRE) -- American Lithium Corp. (“American Lithium” or the “Company”) (TSX-V:LI | OTCQX:AMLIF | Frankfurt:5LA1) announces the appointment of ...

How does this CFO appointment compare to recent similar changes at peer lithium producers and what competitive advantage might it confer? Could the CFO appointment lead to changes in cost structure, operational efficiency, or expense management? How are analysts and rating agencies interpreting the leadership change and its implications for the company’s valuation?
Symbol: LI
Management
22 days ago
Read more globenewswire

ECARX Powers Launch of Geely Galaxy A7, Further Expanding Market Deployment of Antora and Cloudpeak Solutions

SHANGHAI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- ECARX Holdings Inc. (Nasdaq: ECX) (“ECARX” or the “Company”), a global mobility technology provider, today announced that its AI Enhanced Antora® 1000 ...

What is the likely reaction of institutional investors and short‑term traders to this announcement? Will the launch lead to any changes in the company's capital allocation, R&D spending, or partnership strategy? How might this collaboration influence ECARX's market share in the intelligent cockpit segment in China and globally?
Symbol: ECX
Product launch
22 days ago
Read more globenewswire

Costamare Bulkers Holdings Limited Reports Results for the Six-Month Period Ended June 30, 2025

MONACO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Costamare Bulkers Holdings Limited (“Costamare Bulkers” or the “Company”) (NYSE: CMDB) today reported unaudited financial results for the six-month perio...

What technical chart patterns or momentum indicators are emerging in response to the earnings release? Did the results reveal any changes in the company's dividend policy or share buy‑back plans that could affect investor returns? What is the market’s perception of the company’s strategic initiatives, such as fleet expansion or asset sales, based on the results?
Symbol: CMDB
Earnings
22 days ago
Read more globenewswire

Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility

NEW HOPE, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to...

What are the potential implications for the valuation of OBIO's pipeline if the BACKBEAT study demonstrates positive outcomes with the larger patient pool? Are there any anticipated changes in operating expenses or capital requirements associated with the expanded trial that could affect profitability margins? How might the market react to the news sentiment score of 70 and the potential for higher trial enrollment numbers?
Symbol: OBIO
Clinical trials
22 days ago
Read more globenewswire

CONMED Corporation Announces Quarterly Cash Dividend

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on August 7, 2025, payable on October...

What is the historical frequency and consistency of CONMED's dividend payments? How does the dividend payout align with CONMED's strategic growth initiatives? What is the market’s reaction to the dividend announcement in terms of volume and price movement?
Symbol: CNMD
Dividends
22 days ago
Read more businesswire

Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today reported financial results for ...

What is the market's perception of Repare's strategic direction and its long‑term shareholder value creation? How does the company's updated guidance for 2025 revenue and expenses compare to prior guidance? Are there any regulatory or clinical trial risks associated with the newly out‑licensed programs?
Symbol: RPTX
Earnings
22 days ago
Read more businesswire